CD274 and non-small cell lung carcinoma: Several monoclonal antibodies directed to the PD-1 (nivolumab, pembrolizumab) or its ligand PD-L1 (atezolizumab, durvalumab, avelumab) are in clinical development, and nivolumab and pembroluzimab have been approved by the FDA and EMA for use in patients with advanced NSCLC who have previously been treated with chemotherapy (nivolumab has also been approved in Japan)133.